Bach P H, Nguyen T K
BioMedical Research Centre, Division of Biomedical Sciences, Sheffield Hallam University, England, United Kingdom.
Toxicol Pathol. 1998 Jan-Feb;26(1):73-91. doi: 10.1177/019262339802600110.
Analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) are well recognized as a major class of therapeutic agent that causes renal papillary necrosis (RPN). Over the last decade a broad spectrum of other therapeutic agents and many chemicals have also been reported that have the potential to cause this lesion in animals and man. There is consensus that RPN is the primary lesion that can progress to cortical degeneration; and it is only at this stage that the lesion is easily diagnosed. In the absence of sensitive and selective noninvasive biomarkers of RPN there is still no clear indication of which compound, under what circumstances, has the greatest potential to cause this lesion in man. Attempts to mimic RPN in rodents using analgesics and NSAIDs have not provided robust models of the lesion. Thus, much of the research has concentrated on those compounds that cause an acute or subacute RPN as the basis by which to study the pathogenesis of the lesion. Based on the mechanistic understanding gleaned from these model compounds it has been possible to transpose an understanding of the underlying processes to the analgesics and NSAIDs. The mechanism of RPN is still controversial. There are data that support microvascular changes and local ischemic injury as the underlying cause. Alternatively, several model papillotoxins, some analgesics, and NSAIDs target selectively for the medullary interstitial cells, which is the earliest reported aberration, after which there are a series of degenerative processes affecting other renal cell types. Many papillotoxins have the potential to undergo prostaglandin hydroperoxidase-mediated metabolic activation, specifically in the renal medullary interstitial cells. These reactive intermediates, in the presence of large quantities of polyunsaturated lipid droplets, result in localized and selective injury of the medullary interstitial cells. These highly differentiated cells do not repair, and it is generally accepted that continuing insult to these cells will result in their progressive erosion. The loss of these cells is thought to be central to the degenerative cascade that affects the cortex. There is still a need to understand better the primary mechanism and the secondary consequences of RPN so that the risk of chemical agents in use and novel molecules can be fully assessed.
镇痛药和非甾体抗炎药(NSAIDs)是公认的可导致肾乳头坏死(RPN)的一大类治疗药物。在过去十年中,还报道了多种其他治疗药物和许多化学物质,它们在动物和人类中都有可能引发这种病变。目前已达成共识,RPN是可能进展为皮质变性的原发性病变;只有在这个阶段,病变才易于诊断。由于缺乏敏感且具选择性的RPN非侵入性生物标志物,目前仍不清楚哪种化合物在何种情况下最有可能在人类中引发这种病变。使用镇痛药和NSAIDs在啮齿动物中模拟RPN的尝试并未提供可靠的病变模型。因此,许多研究集中在那些导致急性或亚急性RPN的化合物上,以此作为研究病变发病机制的基础。基于从这些模型化合物中获得的机制理解,已能够将对潜在过程的理解应用于镇痛药和NSAIDs。RPN的机制仍存在争议。有数据支持微血管变化和局部缺血性损伤是其根本原因。另外,几种模型乳头毒素、一些镇痛药和NSAIDs选择性地作用于髓质间质细胞,这是最早报道出现异常的情况,之后会有一系列影响其他肾细胞类型的退行性过程。许多乳头毒素有可能通过前列腺素氢过氧化物酶介导的代谢活化,特别是在肾髓质间质细胞中。在大量多不饱和脂质滴存在的情况下,这些反应性中间体导致髓质间质细胞发生局部和选择性损伤。这些高度分化的细胞无法修复,人们普遍认为持续损伤这些细胞会导致其逐渐受损。这些细胞的丧失被认为是影响皮质的退行性级联反应的核心。仍有必要更好地理解RPN的主要机制和次要后果,以便能够充分评估现有化学制剂和新型分子的风险。